Over the last decade, epigenetic therapy by histone deacetylase (HDAC) inhibitors was demonstrated by several preclinical and clinical studies and may become promising for GBM therapy (reviewed in [158,159]). The gene discussed is HDAC9; the disease is glioblastoma.